
FDA Approves Genentech’s Tecentriq Combination for Stage III Colon Cancer Adjuvant Treatment
Genentech’s Tecentriq Receives FDA Approval for Adjuvant Treatment of Stage III dMMR Colon Cancer Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S.…














